肝细胞癌 (HCC) 是一种侵袭性肿瘤，发病较晚。 HCC 的潜在病因正在迅速变化。斯里兰卡的 HCC 因其主要非病毒性病因 (nvHCC) 而独一无二，但缺乏生存数据。数据收集自 2011 年至 2018 年出现 HCC 的患者。其中有 560/568 (98.6%) nvHCC。选择不适合肿瘤特异性治疗的患者（149/560 [26.7%]）。分析了人群特征、人口统计数据、肿瘤特征、生存率和影响生存率的因素。中位年龄为 64 岁（范围 30-88），86% (n = 129) 为男性。多达 124 人 (83%) 患有肝硬化。整体表现得分为80%。 肝硬化筛查中检出近 21/124 个肿瘤。 32 例（21%）肿瘤为单结节，28 例（18%）肿瘤为三个结节，33 例（22%）肿瘤为三个以上结节，56 例（37%）肿瘤为弥漫浸润。 78 例 (52.3%) 存在主要静脉侵犯。 19 例 (12.7%) 出现肝外肿瘤扩散（肺 13 例 [72.2%]，骨骼 2 例 [11.1%]）。接受姑息治疗的患者的中位生存期为三个月（1-43 个月）。在单变量分析中，肿瘤大小和肝硬化状态是重要的预测因子。四分之一的 nvHCC 因生存率低而无法接受治疗。P/126/09/2021。© 2024。印度胃肠病学会。

Hepatocellular carcinoma (HCC) is an aggressive tumor and presents late. The underlying etiology of HCC is changing rapidly. HCC in Sri Lanka is unique due to its predominant non-viral etiology (nvHCC) but lacks survival data.Data was collected from patients who presented with HCC from 2011 to 2018. There were 560/568 (98.6%) nvHCC. The patients who were not candidates for tumor-specific treatment (149/560 [26.7%]) were selected. Population characteristics, demographic data, tumor characteristics, survival and factors affecting survival were analyzed.The median age was 64 years (range 30-88) and 86% (n = 129) were males. As many as 124 (83%) were cirrhotic. The overall performance score was 80%. Nearly 21/124 tumors were detected in cirrhotic screening. Tumors were single nodular in 32 (21%), up to three nodules in 28 (18%), more than three nodules in 33 (22%) and diffusely infiltrating in 56 (37%). The major venous invasions were present in 78 (52.3%). Extra-hepatic tumor spread was seen in 19 (12.7%) (lungs 13 [72.2%], bones 2 [11.1%]). The median survival of patients receiving palliative care was three months (1-43 months). Tumor size and cirrhotic status were significant predictors in univariate analysis.A quarter of nvHCCs were not amenable to treatment at presentation as they had dismal survival.P/126/09/2021.© 2024. Indian Society of Gastroenterology.